Table 2.
Pharmacokinetic profile of developed nanoparticles.
| Parameters | Standard | F3 | F3C |
|---|---|---|---|
| (Mean ±SD) | (Mean ±SD) | (Mean ±SD) | |
| Cmax (ng/ml) | 0.77 ± 0.02 | 5.09 ± 0.37∗∗ | 17.39 ± 3.48 ∗∗∗ |
| Tmax (h) | 1.75 | 2 | 1.5 |
| AUClast (ng.h/ml) | 5.96 ± 0.58 | 40.50 ± 0.82∗∗∗ | 110.57 ± 8.36∗∗∗ |
| AUCtot (ng.h/ml) | 7.30 ± 1.00 | 54.57 ± 4.45∗∗∗ | 120.05 ± 10.32∗∗∗ |
| Kel (h) | 0.07 ± 0.01 | 0.05 ± 0.01 | 0.11 ± 0.03∗∗ |
| T1/2 (h) | 9.34 ± 1.35 | 13.06 ± 3.81 | 6.66 ± 1.74 |
| MRT (h) | 13.54 ± 2.18 | 17.37 ± 2.98∗ | 8.46 ± 1.54∗∗ |
| Relative Bioavailability (%) | 100 | 679.25 | 1854.27 |
∗P < 0.05 significant compared with standard suspension; ∗∗P < 0.01 highly significant compared with normal suspension and ∗∗∗P < 0.001 extremely significant compared with normal suspension.